- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- DNA Damage/DNA Repair
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-Flag magnetic beads
- Anti-Flag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Magnetic Separator
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
Azenosertib (Zn-C3)
Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
Azenosertib (Zn-C3) Chemical Structure
CAS No. 2376146-48-2
Purity & Quality Control
Batch:
Purity:
99.81%
99.81
Products often used together with Azenosertib (Zn-C3)
ZN-c3 has a higher selectivity and better safety profiles compared to Adavosertib, making it particularly well-suited for combination therapies.
Zn-C3 and RP-306 combined inhibition of WEE1 and PKMYT1 exhibits synergism in killing of U2OS cells.
Azenosertib (Zn-C3) Related Products
| Related Products | Adavosertib (MK-1775) PD0166285 | Click to Expand |
|---|---|---|
| Related Compound Libraries | Kinase Inhibitor Library PI3K/Akt Inhibitor Library MAPK Inhibitor Library DNA Damage/DNA Repair compound Library Cell Cycle compound library | Click to Expand |
Signaling Pathway
Biological Activity
| Description | Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research. | ||
|---|---|---|---|
| Targets |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05743036 | Recruiting | Metastatic Colorectal Cancer |
K-Group Beta Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc|Pfizer |
February 27 2023 | Phase 1|Phase 2 |
| NCT05682170 | Recruiting | Acute Myeloid Leukemia (AML) |
K-Group Alpha Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc. |
December 1 2022 | Phase 1|Phase 2 |
| NCT05431582 | Withdrawn | Tumors|Ovarian Cancer|Breast Cancer|Lung Cancer|Pancreatic Cancer |
M.D. Anderson Cancer Center|Zentalis Pharmaceuticals |
December 14 2022 | Phase 1 |
| NCT05198804 | Recruiting | Ovarian Cancer|Platinum-resistant Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer |
K-Group Beta Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals Inc |
January 27 2022 | Phase 1|Phase 2 |
Chemical Information & Solubility
| Molecular Weight | 526.63 | Formula | C29H34N8O2 |
| CAS No. | 2376146-48-2 | SDF | -- |
| Smiles | CCC1(O)CCC2=CC=C(N=C12)N3N(CC=C)C(=O)C4=CN=C(NC5=CC=C(C=C5)N6CCN(C)CC6)N=C34 | ||
| Storage (From the date of receipt) | 3 years -20°C powder | ||
|
In vitro |
DMSO : 100 mg/mL ( (189.88 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.) Ethanol : 100 mg/mL Water : Insoluble |
Molecular Weight Calculator |
|
In vivo Add solvents to the product individually and in order. |
In vivo Formulation Calculator |
||||
Preparing Stock Solutions
Molarity Calculator
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
mg/kg
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
* Indicates a Required Field
Tags: buy Azenosertib (Zn-C3) | Azenosertib (Zn-C3) supplier | purchase Azenosertib (Zn-C3) | Azenosertib (Zn-C3) cost | Azenosertib (Zn-C3) manufacturer | order Azenosertib (Zn-C3) | Azenosertib (Zn-C3) distributor
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.